Study of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatis

A Multicenter, Single-arm, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacokinetics of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatitis

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06162507

Enrollment

Registered

2023-12-08

Start date

2023-12-22

Completion date

2024-07-04

Last updated

2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Brief summary

This is a multi-center, single arm, open-label study to evaluate safety in children patients with moderate-to severe atopic dermatis.

Interventions

BIOLOGICALCM310

CM310 injection

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

6 Years to 11 Years

Healthy volunteers

Inclusion criteria

* With atopic dermatis. * Voluntarily sign the informed consent form.

Exclusion criteria

* Any major surgery planned during the research period. * With intestinal parasitic infection within the first 6 months of screening. * With any previous malignant tumors prior to screening. * With any circumstance that is not suitable to participate in this study.

Design outcomes

Primary

Measure	Time frame	Description
Adverse events	up to week 16	Incidence of adverse events.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026